For millions of women and girls who suffer from urinary tract infections (UTIs) — especially those plagued by stubborn, recurring infections — there’s finally a new medication option on the horizon.
The U.S. Food and Drug Administration (FDA) has officially approved gepotidacin, an oral antibiotic that represents the first in an entirely new class of medications for treating UTIs.
Marketed under the brand name Blujepa, this breakthrough is the first antibiotic specifically for UTIs to receive approval in almost three decades.
A Welcome Option for Hard-to-Treat Infections
Women and girls aged 12 and older dealing with uncomplicated UTIs — those confined to the bladder and not yet spread to the kidneys — are eligible to benefit from Blujepa. This approval couldn’t come at a more critical time, as drug-resistant infections have made treating some UTIs increasingly difficult.
“The new antibiotic is a fantastic event, as there is a significant minority of women with UTIs that have become resistant to the current armamentarium of antibiotics. This gives an option to those who would otherwise need intravenous antibiotics,” says Craig Comiter, MD, a professor of urology and practicing urologist at Stanford Health Care in California.
The Burden of UTIs on Women’s Health
UTIs are the single most common type of bacterial infection affecting women in the United States, impacting an estimated 16 million women annually. More than half of all women will experience a UTI at some point in their lives, and for approximately 30 percent, these infections become a chronic, recurring problem.
The infections occur when bacteria — typically from the digestive tract — migrate into the urinary system, causing inflammation and discomfort. UTIs most often cause symptoms such as a persistent urge to urinate, burning pain while urinating, and discolored or foul-smelling urine. If left untreated, they can lead to serious complications, including kidney infections.
Blujepa’s Approval Backed by Promising Clinical Results
The FDA based its approval of Blujepa on two pivotal phase 3 clinical trials known as EAGLE-2 and EAGLE-3. In these studies, the new drug was compared head-to-head with nitrofurantoin, a commonly prescribed antibiotic for uncomplicated UTIs.
In the EAGLE-2 trial, Blujepa proved to be just as effective as nitrofurantoin, with 50 percent of patients achieving complete symptom resolution and no signs of bacterial infection compared to 47 percent for nitrofurantoin. Notably, the EAGLE-3 trial showed even better results for Blujepa, with a 59 percent success rate versus 44 percent for the older medication.
“Blujepa appears to be about as effective as the currently available options,” says Dr. Comiter. “But when bacteria are resistant to other antibiotics, choices are limited, and so this gives us another important choice.”
Side Effects: What Patients Should Know
Like most antibiotics, Blujepa does come with some side effects, though they were generally mild to moderate during the clinical trials. Gastrointestinal issues were the most frequently reported, with diarrhea affecting 14 to 18 percent of participants and nausea occurring in nearly 9 percent. Serious or life-threatening side effects were not reported, making it a well-tolerated option for most patients.
Addressing the Growing Threat of Antibiotic Resistance
A primary driver behind the development of Blujepa is the growing problem of antibiotic resistance in the bacteria responsible for UTIs. Most infections are caused by Escherichia coli, a common bacterium found in the intestines. Traditionally, UTIs caused by E. coli were easily treated with a short course of antibiotics. However, this is changing rapidly.
Evidence suggests that over 90 percent of UTI-causing bacteria are resistant to at least one common antibiotic, and nearly 80 percent show resistance to two or more drugs. This alarming trend highlights the urgent need for new treatment options.
“Resistance is acquired, generally ascribed to overuse of antibiotics, but it is a natural part of bacterial evolution and may be unavoidable,” explains Dr. Comiter.
Blujepa is especially important for treating infections caused by drug-resistant bacteria such as ESBL (extended spectrum beta-lactamase) and MDR (multidrug-resistant) strains, which are difficult to eliminate with existing medications.
“This approval will also help patients everywhere who have multiresistant infection,” Comiter adds.
When Will Blujepa Reach Patients — and at What Cost?
According to Lyndsay Meyer, director of U.S. Corporate Media Relations at GSK, Blujepa is expected to hit U.S. pharmacies by summer 2024. While pricing details have not yet been announced, Meyer noted that, “Details are forthcoming.”
Given that most antibiotics currently prescribed for UTIs are inexpensive generics, the introduction of a new branded medication like Blujepa may bring cost considerations into the equation for patients and healthcare providers alike.
“Cost is always a consideration, and this treatment should be ‘saved’ for those bacteria that are known to be resistant to current antibiotics,” advises Dr. Comiter.
Looking Ahead
As the medical community continues to grapple with the consequences of antibiotic resistance, the approval of Blujepa represents a significant milestone in infectious disease treatment. Not only does it provide a new lifeline for those battling difficult-to-treat UTIs, but it also signals progress in the fight against superbugs.
For millions of women dealing with recurrent or drug-resistant bladder infections, this new option may soon offer much-needed relief — and a brighter outlook for the future of UTI care.
Recommended For You
